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The immune system is the first line of defense against cancer. The immune system
regularly detects and destroys cancer cells. Despite this continuous protection, certain
cancers are able to escape detection or destruction by the immune system. Research in
recent decades has addressed the possibility of enlisting the help of the immune system
to detect and destroy cancer cells. One compelling treatment uses a laser, an immune
stimulant called glycated chitosan (GC), and a light absorbing dye called indocyanine
green to convince the immune system to incite a systemic attack against both primary
and metastatic tumors. In successful treatments, all tumors are completely destroyed and
patients develop long-term immunity against tumors. While attempting to locate and
destroy tumor cells, the cells of the immune system face competing pressures. On one
hand are the immune cells that detect and attempt to control tumor cells (typically the
target of the immune response is a foreign invader), and on the other hand are the immune
cells that prevent the response from growing dangerously out of control. By policing certain
immune cell populations, regulatory T cells (Tregs) play an important role in keeping the
overall immune response under control. But, in doing so, these Tregs indirectly protect
cancer cells.
We describe post-treatment immune dynamics with mathematical models, and predic-
tions of clinical treatment outcomes can be drawn from model predictions. Currently we
emphasize the role of cytotoxic T cells and dendritic cells in the laser-initiated immune
response, but we have also studied the roles of B cells and helper T cells. Our model is
based on experimental studies with the dimethylbenza(a)nthracene-4 (DMBA-4) metastatic
mammary tumor line in the rat animal model. We have used our model to determine clinical
outcomes based on the effects of two key treatment factors: the dose and role of GC, and
the manipulation of Treg activity. Treatment outcome is improved by the pro-immune
stimulatory properties of GC and worsened by the proposed pro-tumor activity of Tregs.
The results from our studies indicate potential treatment designs that could be used to
improve treatment outcome or highlight additional areas that should be targeted for future
experimentation with animal models.
I would like to dedicate this to my family and my wonderful wife. You have all been
instrumental in my development into the person I am today.
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To begin our work mathematically modeling a potential mechanism underlying a novel
anti-tumor immunotherapy, we give a brief introduction to cancerous tumor growth, cancer
immunotherapies, existing cancer models, and immunology. The activities of the immune
system cells listed are not limited to anti-tumor immunity. However, the descriptions of
each cell type will be limited to the proposed role that each cell plays in the anti-tumor
laser immunotherapy treatment.
1.1 Cancerous Tumor Growth
Cancerous tumors form when one or more of an organism’s cells ceases to operate in
accordance with its normal cellular cycle. This can be caused by random mutations in a
segment of a cell’s DNA that controls for programmed cell death or apoptosis. This can also
be caused by a mutation in the segment of DNA that controls cellular division, in which a
cell makes a copy of itself [1, 2, 3]. An organism’s innate immune system, the cells of its
immune system requiring no preliminary activation to combat invaders, constantly surveys
its surroundings. When a cancerous cell is recognized, innate cells can kill it [4]. However,
when all of these checkpoints have failed to eradicate cancer cells, uncontrolled proliferation
and migration of cancer cells can occur. This uncontrolled cancer cell growth can interfere
with normal organ function on a scale that can cause the death of an organism. Cancer cell
migration, or metastasis, makes the task of curing a patient of cancer much more difficult.
An isolated tumor that has not metastasized stays fixed in a single location, so it is easier to
locate for treatment. However, when tumor cells branch off a primary tumor and spread to
other locations, the act of surgically removing tumors of the primary tumor cell line can be
tremendously difficult [1, 2, 3]. This implies that cancer therapies must be able to eradicate
tumors in numerous, and possibly unidentifiable, locations.
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1.2 Cancer Immunotherapies
There are many types of therapies for cancer aimed at using immune components,
termed immunotherapies. Numerous vaccines have been created that have caused significant
regression of cancerous tumors in some patients [5, 6]. There are also viral therapies that
aim to use oncolytic (cell lysing) viruses to infect and kill tumor cells [7, 8, 9]. This therapy
can also indirectly inform the immune system that cancer cells are present due to the fact
that a patient’s immune system can recognize the presence of viruses [8, 9]. When immune
cells recognize that a cancer cell is infected with a virus, they will force the cancer cell
into apoptosis to kill the cell [8, 9]. It is also possible to extract a patient’s immune cells,
train them to fight cancer, and then re-inject them back into the patient. This immune cell
extraction and training before re-injection has been shown to be quite effective in treating
cervical cancers [10].
Anti-tumor laser immunotherapy is a promising approach to treating cancerous tumors
[11, 12, 13, 14, 15, 16, 17, 18]. Laser immunotherapy uses a laser to kill cancer cells, which
releases a cancer signal to the immune system, in the form of proteins. With the aid of
immune stimulants, this therapy has been shown to be quite effective in treating patients
with metastatic tumors [11, 12, 13, 14, 15, 16, 17, 18]. Our focus is the anti-tumor laser
immunotherapy performed in the laboratory on rats inoculated with metastatic mammary
tumors [15].
1.3 Mathematical Models of Cancer Immunology
The concept of modeling immunological responses to cancer is certainly not new. There
is a balance between biological detail and mathematical simplicity when writing models
of biological processes. Many models are polarized towards mathematical complexity, and
include less explicit treatment for individual immune cells. The more complex mathematical
models frequently address three components: an overall cancer or tumor burden, an immune
effectivity, and drug or chemical concentration affecting the immune component [19]. This
type of model is phenomenological in nature, which makes biological interpretation of
variables and parameter units less obvious. However, the limited number of equations in
such a model implies fewer unknowns which can make parameter estimation more feasible.
Including a more explicit treatment of individual immune cell types makes models more
descriptive and easier to explain in a biological context. Increased biological detail implies
an increase in the number of variables and model parameters, which is demonstrated in
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[20, 21]. These ordinary differential equation models explicitly include components for
cancer, several types of immune cells, or immune-affecting chemicals and chemotherapy
drugs. One incentive in writing a more biologically descriptive model is that it can be
used in a variety of contexts. In such models, one type of treatment can easily be replaced
by another to analyze multiple treatment scenarios. Models using immunotherapy and/or
chemotherapy of cancer could be altered slightly to incorporate an oncolytic virotherapy
model [22].
1.4 Categories of Immunity
The immune system has two major categories: the innate immune system and the
adaptive immune system. The innate immune system, named for the fact that it is common
among all animals, includes cells that are always actively seeking and destroying invaders
that have entered an organism [4]. Innate immunity is the first line of defense against a
new threat to an organism [4]. The adaptive immune system, on the other hand, must
be activated in order to combat an invader [4]. Adaptive immunity is appropriately called
“adaptive” because each threat type will lead to a unique secondary, or adaptive, immune
response. The adaptive component of the immune system is capable of remembering a past
invader or threat, which means that an organism’s immune system will progressively adapt
to the host’s surroundings [4].
1.5 Dendritic Cells (DCs)
The adaptive immune response to cancerous tumors begins with the uptake and pro-
cessing of tumor antigen, which are the roles of dendritic cells [23, 24, 25, 26, 27, 28, 29].
Tumor antigen consists of tumor cell protein fragments released by laser-induced cellular
apoptosis [30]. Laser irradiation of a primary tumor usually lasts for about 10 min-
utes, which causes the release of tumor antigen to the neighboring tissues and blood
[11, 12, 13, 14, 15, 16, 17, 18]. Naive or inactive dendritic cells then take in antigen, which
initiates and drives their activation process [23, 24, 25, 26, 31, 27, 28, 32, 29, 33, 34, 35]. The
initial stage of activation is one of migration to the surrounding lymph nodes, during which
dendritic cells continually process antigen into peptides and load them onto their surface
for presentation to naive cytotoxic T cells, helper T cells, and B cells [23, 26, 31, 36, 34, 35].
Upon reaching the lymph nodes, dendritic cells are fully activated and capable of presenting
to several naive T and B cells. As long as tumor cell killing is occurring, antigen will
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continually be released via tumor cell apoptosis. Therefore, dendritic cells will continue to
carry out this process until all tumor cells have been eradicated [11, 12, 13, 14, 15, 16, 17, 18].
1.6 T Cells
T cells perform a variety of tasks after activation via antigen presentation. Each type
of T cell has a unique role in the immune response, ranging from killing tumor cells to
defending tumor cells [37, 38, 39].
1.6.1 Cytotoxic T Lymphocytes (CTLs)
Before antigen presentation, naive CTLs remain in the lymph nodes [40]. Once antigen
is presented to a naive CTL, the cell becomes activated and leaves the lymph node to
begin clonal proliferation [41]. In this process, CTLs drastically increase in number in
proportion to the severity of the infection (surviving primary and metastatic tumor cells).
After proliferation, CTLs travel to all tumor sites to begin infiltrating tumors and killing
tumor cells [40]. The lifespan of CTLs will depend on how active they are at the “battle site”
[4], how effective immunosuppressive activity is in the tumor microenvironment [42, 43, 44],
and whether or not these cells are restimulated by other immune cells [4].
1.6.2 Helper T Cells
Similar to CTLs, helper T cells remain in the lymph nodes in a naive state prior to
antigen presentation [45, 4]. Once activated via antigen presenting dendritic cells, helper T
cells leave the lymph nodes to proliferate [45, 4]. Unlike CTLs, activated helper T cells are
involved in the activation or stimulation of other immune cells [45, 4, 46, 47, 48, 49, 50].
Activated helper T cells have been shown to help CTLs proliferate by releasing a growth
factor called interleukin 2 (IL-2) [47, 50, 45, 46, 4]. During B cell-helper T cell contact,
activated helper T cells can provide a stimulatory influence on antigen-primed B cells with
a type of surface protein called CD40L [4].
1.6.3 Regulatory T Cells (Tregs)
In order to achieve the desired clinical outcome (complete tumor cell eradication), the
immune response must continue until all tumor cells have been eradicated. However,
complete eradication also needs to be followed by a cessation of the adaptive immune
response to prevent autoimmune disease [4]. In general, regulatory T cells help bring the
immune response to an eventual end in several important ways. Regulatory T cells can kill
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antigen presenting dendritic cells, and alter dendritic cell function to become toxic towards
CTLs [42]. Tregs can also hinder the activation and migration of dendritic cells [51]. Tregs
are also capable of directly killing active CTLs or decreasing proliferation rates of active
CTLs [42, 4]. This type of suppressive activity actually prevents an organism’s own immune
system from attacking healthy cells once the threat is over [4]. Unfortunately, this means
that Tregs aid cancerous tumors to actually keep CTLs from killing tumor cells [51, 43]. One
of the primary focuses of cancer immunotherapy is adequately suppressing Tregs to allow
for an immune response sufficient to eradicate all tumor cells while not overly suppressing
Tregs, which can cause autoimmune disease [52, 51, 43, 44].
1.7 B Cells and Antibodies
B cells congregate in the lymph nodes until antigen has been presented and eventual
activation occurs [4]. However, in many cases these cells still require an additional stimulus
from activated helper T cells to be activated [4]. After antigen presentation and a secondary
stimulus via activated helper T cells has occurred, B cells become fully activated plasma
B cells that can produce antibodies specific to the laser irradiated tumor cells [12, 53, 4].
These antibodies then move to the site of tumors and “tag” them for destruction by innate
immune cells like natural killer cells (NKs) or macrophages [12, 53, 4, 54]. Activated B cells
can also activate naive helper T cells [4].
1.8 Immunoadjuvants and Elements of Treatment
Immune adjuvants affect different components of the immune system in a variety of ways.
Ultimately, their purpose is to make the immune response more efficient [55]. Adjuvants
are used with vaccines in order to help facilitate antigen uptake and processing via antigen
presenting cells like dendritic cells [55]. They can also increase dendritic cell migration rates
and make antigen presentation to cytotoxic T cells more efficient [55]. In anti-tumor laser
immunotherapy, the immune adjuvant GC is injected intratumorally either before or after
laser treatment [11, 12, 13, 14, 15, 16, 17, 18]. It is not entirely known exactly how GC
affects the immune system, but one observed outcome is that macrophages and natural killer
cells become more active at tumor sites as GC concentration increases [56]. However, its
administration has been shown to lead to a more robust adaptive immune response similar
to that of other adjuvants [12, 15, 18, 56]. Therefore, we analyze the effects of GC based
on the assumption that this substance behaves similarly to other immune adjuvants.
CHAPTER 2
MATHEMATICAL MODEL
We have written and analyzed a model that includes only DCs, CTLs, tumor cells, and
tumor antigen (see appendix for related models). However, we are able to implicitly study
the effects of Tregs, helper T cells, B cells, and antibodies by varying parameters in our
model. This allows us to analyze a model that is roughly half the size of the full system and
has far fewer parameters (compare the model in Equations 2.1 to the similar, but expanded,
model in Equations A.1). Based on work presented in [11, 12, 13, 14, 15, 16, 17, 18], we iden-
tify a subset of host immune cells activated during tumor immunotherapy that contribute
to tumor eradication (see Figure 2.1). We propose that these cells and their interactions































Figure 2.1. Conceptual model of antitumor laser immunotherapy. After LIT, antigen (Ac)
is released. Naive dendritic cells (D0) take up antigen, begin migrating (DM ), and reach
lymph nodes (DL) to present antigen to naive CTLs (T0). CTLs enter stages of proliferation
(T1 − Tn). After proliferation, CTLs (TA) kill primary (P ) and metastatic (M) tumors.
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2.1 Mathematical Model
The model is a system of first-order, nonlinear, ordinary differential equations that are
nearly autonomous, with the exception of a forcing function. The function φ(t) is a unitless
time-dependent treatment function responsible for primary tumor cell death driven by the
laser-tissue interaction. In Equations 2.1, we track each stage of maturation of DCs and





































































− (ω + εAcαD0)Ac
(2.1)
Sample results of the model given in Equations 2.1 are illustrated in Figure 2.2 and Fig-
ure 2.3, which are explained in greater detail in the subsequent section (see Chapter 3,
specifically Section 3.2). Model parameters and units are shown in Table 2.2.
Each of the equations governing immune dynamics is derived similarly based on the
underlying biological dynamics. Initially, there is a naive (inactive) population of cells
that eventually gives rise to intermediate and active populations. Both DCs and CTLs
go through intermediate developmental phases before complete activation occurs. Each
immune population naturally decays due to mortality at some natural rate, δDi for DCs and
δT0 for CTLs. Naive dendritic cells (D0) are produced at a constant rate sd. Naive dendritic
cells interact with tumor antigen (Ac) at a mass action rate α which drives a transition into
the migratory dendritic cell state (DM ) with efficiency εM . Migration occurs at rate η, as
migrating dendritic cells move to the lymph nodes. Upon some fraction (εL) reaching a
lymph node, we consider dendritic cells to be fully activated lymphatic dendritic cells (DL).
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Similarly for CTL equations, there is a constant supply rate st into the naive population
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Figure 2.2. Predicted tumor-immune dynamics demonstrating the general case of suc-
cessful treatment. Primary and metastatic tumor burden data from [15]. In the upper left
plot, solid blue dots are primary tumor burden experimental data and solid red triangles
are metastatic tumor burden experimental data. Solid, dashed, and dotted curves in each
plot are model simulations. Vertical dashed line in each plot represents the time of laser
treatment at t = 10 days. In the lower right plot, CTL dynamics are shown for n = 8
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Figure 2.3. (Left) Progression through the stages of proliferation with the highest curve
(t ≥ 40) being the active CTLs able to kill tumor cells. For t ≥ 40, the lowest curve
represents the first proliferative stage. Each successively higher curve represents the ith
proliferative stage for i = 2, 3, . . . , 8. (Right) The same CTL proliferative stages on a
smaller scale t ∈ [9, 15].
several stages of proliferation (T1 − Tn) where we chose n = 8 based on proliferation data
in the literature [57]. During the proliferative stages, each cell will clone itself, expanding
its lineage by a factor εi. This expansion gives rise to the i
th-stage equation in the model.
Proliferative T cells move from one stage to the next at rate ξ. After the nth stage, CTLs
have fully proliferated and become completely activated (TA) and begin killing tumor cells.
Though not modeled, CTLs can be re-stimulated by other immune cells so that they live
for extended periods in the active state, but these cells generally die more quickly [4]. Thus,
we introduce a scaling factor k to account for increased CTL death.
With initial conditions at 105 cells, the primary tumor cells (P ) grow exponentially
at rate γp. We assume that primary tumor cells metastasize exponentially at some rate
µ giving rise to metastatic tumor cells (M) with efficiency σ. We do not address multiple
metastatic tumors explicitly, but instead track the aggregate population. The population of
metastatic tumor cells in our model is the total amount of cells that have left the primary
tumor and continue to expand. Once tumor cells become metastatic, they continue to
grow exponentially at rate γM . Killing of tumor cells is assumed to be proportional to the
10
effectivity of CTL killing
TA
ci+TA
. Ultimately, the per capita killing rate λi and the constant
ci determines the effectiveness of killing.
Tumor antigen is partly created by laser irradiation of the primary tumor, which is
modeled by a time-dependent function φ(t). This function is equal to zero until time of
treatment at t = 10 days. It is defined as 0 for 0 ≤ t < 10 and as 0.1(t − 10)e−(t−10) for
t ≥ 10. Antigen is also created when CTLs kill primary and metastatic tumor cells which






in the (Ac) equation. Antigen is
naturally cleared at rate ω and is taken up by naive DCs at rate α with efficiency εAc .
Tumor killing will continue, whether it is effective or not, until all antigen has been cleared.
2.2 Parameterization
Since patients have innate immune parameters in the absence of tumors, we have a group
of parameters associated to the patient himself (e.g. constant supplies for naive populations
st and sd). Still other parameters may be more closely associated to the tumors, such as
growth (γp and γM ) and antigenicity (ρ and σ), so we separate these parameters from the
rest. In planning and analyzing numerical experiments with Treg and GC effectivity, we are
able to partition parameters according to each category of influence. These relationships
are illustrated in Figure 2.4, which shows all of the treatment parameters organized into
essentially non-overlapping groups within the patient. A detailed list for each categorical
parameter is given in Table 2.2.
The patient encompasses all cellular and molecular components, so this can be defined
as the universal set of the diagram. Subsets for Treg and GC parameters intersect because
both have influence on the DC migration rate η. Similarly, GC and cancer parameters
intersect since both affect the rate of metastasis µ. Specific numerical values and ranges


























Figure 2.4. Parameters categorized by innate patient associated parameters, cancer
associated parameters, Treg associated parameters, and GC associated parameters. The
patient parameter set includes all parameter subsets. The parameter εi is indexed by
i = 1, 2, . . . , 8 for proliferating cells and A for fully-activated cells.
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Table 2.1. Symbols, values, units, and references for patient parameters used in the system
given in Equations 2.1. These parameters are those that are innate to the patient in the
absence of cancer. Parameters without references were estimated by minimizing the root
mean squared error (RMSE) with LHS from data in [15].
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Table 2.2. Symbols, values, units, and references for regulatory T cell, cancer, and glycated
chitosan parameters used in the system given in Equations 2.1. Treg dynamics, cancer
dynamics, and GC dynamics. Parameters without references were estimated by minimizing
the root mean squared error (RMSE) with LHS from data in [15].












σ 0.45 M cellsP cell
estimated
ρ 100 Ac moleculesP cell · day
estimated





















α 0.012 1Molecule · day
estimated











ANALYSIS OF MATHEMATICAL MODEL
In order to understand the intricate details of anti-tumor laser immunotherapy as
described in [11, 12, 13, 14, 15, 16, 17, 18, 56], the following questions must be answered.
1. What is the baseline growth pattern for the DMBA-4 metastatic mammary tumor cell
line used in animal model studies for anti-tumor laser immunotherapy?
2. To link mathematical modeling results to animal model experimental data, can we
classify model dynamics and relate results to animal model data?
(a) What are the qualitative and quantitative properties of what would be considered
successful or failed treatment?
(b) In performing sensitivity analysis with parameters, what does the model predict
about the diversity of treatment outcomes?
(c) What features of anti-tumor laser immunotherapy can be modified and what impact
would these changes have on treatment outcome or post-treatment dynamics?
3. What is the role of GC in the development and dynamics of the immune response?
(a) How does GC affect tumor-immune dynamics after laser treatment, and how can
these effects be captured by and studied with a mathematical model?
(b) What model parameters could be changed to study the effects of varying levels of
glycated chitosan effectivity?
4. The importance of Treg suppression on immunotherapy outcome has been demonstrated
experimentally. Which modeled components are influenced by Treg regulation and would
benefit from Treg suppression?
(a) Since the model does not explicitly include Tregs, how can their effects be modeled
implicitly by changing key parameters that correspond to levels of Treg immuno-
suppressive activity?




In order to more comprehensively explore the post-treatment dynamics that the model
predicts, it is necessary to solve the model for a considerably large number of different
parameter sets. It is desirable to minimize the number of parameter sets that must be
sampled to develop an overall concept of the model’s behavior. We also sample parameters
within a pre-defined range to adhere to as many biologically known parameters as possible.
To accomplish these goals, a method called Latin Hypercube Sampling (LHS) is used to
randomly generate 1000 different parameter sets [61].
3.1.1 Latin Hypercube Sampling
For LHS, each parameter is considered a random variable with some probability distribu-
tion function [62, 61]. Each parameter distribution is then divided into n intervals of equal
probability from which values are selected without replacement [62, 61] (see Figure 3.1).
Thus, if there are k parameters and one desires to sample n values for each parameter from
its distribution, then the final result will be an n× k matrix of n generated values for each
of the k parameters.
The LHS method provides efficient approximation of each probability distribution func-
tion due to the fact that it allows only a single value to be randomly selected in any one
interval of the n-interval subdivision of the parameter probability distribution function
[62, 61]. The random nature of this selection technique also ensures that a large portion
of the parameter space is sampled [62]. LHS is superior to simple random sampling of
parameters, with the assumption of some probability distribution function for a given
parameter, due to more efficient and broad exploration of each parameter space [62, 61]
Subdivided Parameter Distribution




Figure 3.1. Example of how
the uniform distribution for each
parameter is divided into equally
probable intervals from which sam-
pling will take place without re-
placement. Sampling the uniform
distribution with equally probable
intervals implies that the intervals
are all of the same length. Assum-
ing a different distribution would































































































































SRS Uniform With Marginal Distributions
Figure 3.2. Scatterplot of 50 points in the unit plane sampled with (on left) random LHS
and (on right) simple random sampling (SRS) of the uniform distribution on [0,1]. Marginal
distribution histograms above and to the right scatterplot show the efficiency of random LHS
and SRS in estimating the uniform distribution on [0,1]. Based on this comparison between
LHS and SRS, it is clear that LHS is a better approximation of the uniform distribution
for the 50 points.
(see Figure 3.2).
Implementation of the Latin Hypercube design for sampling model parameters was done
using the randomLHS(n, k) function in the R [63] ‘lhs’ package [64], where n is the number
of generated parameter sets and k is the number of parameters. With the randomLHS()
function, values for each parameter are selected randomly from the uniform distribution
on [0, 1]. We constrained parameter values since biological rates are not arbitrary, so we are
able to define a minimum (pMin) and a maximum (pMax) for each parameter. We choose
pMin and pMax to be a scaled multiple of the baseline parameter value. In the context
of analyzing model sensitivity to changes in parameter values, the assumption of a uniform
distribution for each parameter could be replaced by another distribution. However, the
qualitative outcomes of model simulation will be the same regardless of the distribution
since sampled parameters will be scaled to be between pMin and pMax.
Once all n sets of parameters have been randomly selected, the result is an n×k matrix
(Latin Hypercube) where the ijth entry is the ith selection of the jth parameter. After the
n× k matrix is generated, parameters must be scaled so that they remain confined to our
pre-defined range. Transformation is calculated by
17
pGen = pGen(pMax− pMin) + pMin
where pGen is one of the generated parameter values in the n×k matrix with corresponding
maximum and minimum values pMax and pMin. Since the parameter distribution is
defined to be uniform on [0, 1], the maximum value that pGen can have is 1. If this is the
case, then the above formula reduces to
pGen = pMax
where pGen is the given maximal value within its pre-defined range. Similarly, the minimum
value pGen can have is 0. If this is the case, then the rescaling formula becomes
pGen = pMin
where pGen is the given minimal value within its pre-defined range. After all entries in the
n×k matrix have been rescaled, the result is a new n×k matrix with n randomly generated
values for all k parameters such that each value is within its allowable range [pMin, pMax].
3.2 Predictions of Treatment Outcomes
Treatments are typically performed 10 - 15 days after approximately 105 viable DMBA-4
metastatic mammary tumor cells are injected into each rat [12, 13, 14, 15, 16, 17, 18].
Tumors are injected with a solution composed of a photosensitizing agent called indocyanine
green and the immunoadjuvant glycated chitosan, and then irradiated for about 10 minutes
[12, 13, 14, 15, 16, 17, 18]. Post-treatment, the primary tumor continues to grow until it
reaches a peak in a range of 30 - 50 days following treatment [12, 13, 14, 15, 16, 17, 18].
Once a global peak has been reached for primary tumor burden, tumors begin to shrink in
size to eventual depletion within 100 days after treatment [12, 13, 14, 15, 16, 17, 18]. Since
tumor burden of treated rats in these experiments exhibits exponential growth and decay,
the mathematical model takes this into account using the simple exponential population
growth model.
The model produces the general case of successful treatment outlined above with data
from [15]. The model simulation of the general treatment dynamics for tumor burden
shown in [12, 13, 14, 15, 16, 17, 18], as well as the associated immune system dynamics
predicted by the model is shown in Figure 3.3. Model solutions were found using lsoda()
function in the R ‘deSolve’ package [65]. Using LHS of patient parameters, 1000 parameter
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Figure 3.3. Reproduced from Figure 2.2 in Section 2.1. Predicted tumor-immune dynamics
demonstrating the general case of successful treatment. Primary and metastatic tumor
burden data from [15]. In the upper left plot, closed black dots are primary tumor burden
experimental data and open triangles are metastatic tumor burden experimental data. Solid
and dashed curves in each plot are model simulations. Vertical dashed line in each plot
represents the time of laser treatment at t = 10 days. In the lower right plot, CTL dynamics
are shown for n = 8 proliferative stages. The orange curve in the lower right plot is the




minimized the root mean squared error was chosen to produce Figure 3.3. The data chosen
for comparison is in [15]. The upper left-hand plot in Figure 3.3 shows model simulation for
primary and metastatic tumor burdens with tumor burden data for each tumor type. The
tumor burden simulation reflects experimental observations since the tumor burden curves
increase to a peak between days 20 and 40, and then gradually decay to zero by the end of
the simulated period. This figure also shows the dynamics of tumor antigens. The model
simulation shows that there is an abrupt increase due to laser treatment and CTL-mediated
tumor cell killing. Antigen is slowly cleared as the tumor burden curves decay to zero.
In the lower left plot of Figure 3.3, dendritic cell dynamics are shown. The simulation
shows an initially existing population of naive dendritic cells that quickly decays due to laser
treatment at t = 10 days. These naive cells quickly become migratory cells, which then
become lymphatic dendritic cells. The solid black curve in the dendritic cell plot represents
the number of lymphatic dendritic cells. Since the tumor burden curves gradually decay
until the end of the treatment simulation, the lymphatic dendritic cell curve does not
significantly deviate from its maximum.
The lower right plot of Figure 3.3 shows model simulation for CTL dynamics. The
simulation shows an initially existing population of naive CTLs that quickly decays due
to lymphatic dendritic cell interaction. The solid red curve represents the total number
of actively killing CTLs after all of the proliferative stages have been completed. This
simulation shows the slight delay between CTL activation and the introduction of CTLs to
the tumor sites. Simulated curves for actively killing CTLs quickly increase to a maximum
between days 40 and 50, and then gradually decay until the end of the simulated period.
Model simulation of each proliferative CTL stage and the actively killing CTLs is shown
in Figure 3.4. The lowest curve (t ≥ 40) in this plot represents the first proliferative stage.
Each successively higher curve represents the ith proliferative stage (for i = 2, 3, . . . , 8). The
solid red curve represents the actively killing CTL population. This simulation comes from
the same solution as shown in Figure 3.3, where proliferative stages were summed to draw
focus on the active CTL stage.
In experimentally treated animals, there are several types of qualitative treatment out-
comes ranging from tumor clearance resulting in patient survival to tumor escape resulting
in the death of the patient [11, 12, 13, 14, 15, 16, 17, 18]. Based on the results of animal
experiments [11, 12, 13, 14, 15, 16, 17, 18], one of the following clinical outcomes is assigned
to each model simulation (see Figure 3.5):
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Clearance - tumors are controlled quickly, primary tumor burden does not exceed 3×1010
cells, and primary tumor burden is below 100 cell by the end of the simulated study
period (solid green curves)
Slow Clearance - primary tumor burden clears slowly but not completely, there has not
been a relapse, and primary tumor burden does not exceed 3×1010 cells (dashed blue
curves)
Relapse - initial clearing of primary tumor burden with eventual re-growth to an obvious
peak, and primary tumor burden does not exceed 3×1010 cells (dotted purple curves)
Death - primary tumor burden exceeds 3×1010 cells and study animal is sacrificed (dashed
and dotted red curves)
It is known that different organisms within the same species routinely exhibit vastly
different immunities [4]. For the mathematical model, these immunological variances are
expressed by changes to model parameters. In line with the concept of random immune vari-
ability, 1000 different parameter sets were randomly generated by LHS. For each parameter






















Stage 8 Figure 3.4. Reproduced from
Figure 2.3 in Section 2.1. Pro-
gression through the stages of
proliferation with the highest
curve (t ≥ 40) being the active
CTLs able to kill tumor cells.
For t ≥ 40, the lowest curve
represents the first proliferative
stage. Each successively higher
curve represents the ith prolifer-























































Figure 3.5. Model simulations produced as patient parameters vary about baseline param-
eter set using LHS. All qualitatively different outcomes, as defined previously (Section 3.2),
are represented. (A) Changes in primary tumor burden as patient parameters vary. (B)
Changes in metastatic tumor burden as patient parameters vary.
3.3 Modeling the Effects of Glycated Chitosan (GC)
Immunoadjuvants are used to stimulate the immune system to achieve a more robust
immune response [66, 55]. In [11, 12, 13, 14, 15, 16, 17, 18, 56], the immunoadjuvant
glycated chitosan is used to stimulate the immune system in antitumor laser immunotherapy.
Immunoadjuvants have been shown to increase antigen uptake, aid in dendritic cell activa-
tion and maturation/migration, and aid in T cell activation [66, 55]. With the reasonable
assumption that glycated chitosan adopts a similar mode of immune stimulation, we can
model these effects by changing corresponding model parameters. Parameters that change
with varying levels of GC effectivity are:
• α - rate at which dendritic cells interact with antigen and become activated
• η - rate of dendritic cell migration
• εM - efficiency of naive to migratory dendritic cell conversion
• β - rate at which lymphatic dendritic cells interact with and activate naive CTLs
• µ - rate of primary tumor cell metastasis
Using LHS of GC parameters, 1000 different GC parameter sets were randomly gener-
ated. For each parameter set, the model was solved with fixed initial conditions to determine
22
model sensitivity to changes in GC levels. Simulations were qualitatively classified by
changes in overall tumor dynamics as outlined previously in Section 3.2.
Model sensitivity to changes in GC parameters is demonstrated in Figure 3.6. The
first column of this figure represents tumor burden dynamics for each outcome. The most
noticeable change from the effects of GC is shown in the second column, which represents
dendritic cell dynamics for varying degrees of GC effectivity. In the last row, the extremely
low number of DCs in the lymph nodes affects the eventual number of activated CTLs. This
in turn produces a tumor burden that is uncontrolled, which corresponds to patient death.
A comparison of each clinical outcome on the same plot for selected cell types is given
by Figure 3.7. Figure 3.7(A), showing primary tumor burden dynamics, illustrates how
changes in GC parameters can alter clinical outcome from clearance (solid green curve) to
death (dotted red curve). Results are similar in Figure 3.7(B), but with metastatic tumor
burden instead. Figure 3.7(C-D) may seem somewhat contradictory since there are more
lymphatic dendritic cells and CTLs in the slow clearance case. However, from Table 3.1,
the rate of metastasis is larger in the clearance case when compared to the slow clearance
case. This leads to greater decline in primary tumor burden since tumor cells are both
metastasizing and being killed by CTLs simultaneously.
Table 3.1. Changes in GC parameters from one clinical treatment outcome to the next. η
is the DC migration rate to lymph nodes, β is the lymphatic DC - CTL interaction rate, εm
is the naive to migratory DC efficiency, µ is the rate of metastasis, and α is the interaction
rate between naive DC and free antigen.
Outcome η β εM µ α
Clearance 1.003541 0.0001248971 0.6624288 0.1869302 8.190×10−5
Slow
Clearance
0.9220876 3.157×10−5 0.8573427 0.05970596 1.267×10−5
Dead 1.391807 4.086×10−5 0.04326611 0.03730337 7.844×10−5
changes in GC parameters can alter clinical outcome from clearance (solid green curve) to
death (dotted red curve). Results are similar in Figure 3.7(B), but with metastatic tumor
burden instead. Figure 3.7(C-D) may seem somewhat contradictory since there are more
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lymphatic dendritic cells and CTLs in the slow clearance case. However, from Table 3.1,
the rate of metastasis is larger in the clearance case when compared to the slow clearance
case. This leads to greater decline in primary tumor burden since tumor cells are both































































































Figure 3.6. For each clinical outcome (corresponding to rows) defined by tumor dynamics,
simulations for each cell type are shown. Clinical outcome is highly correlated with the
maintenance of CTLs throughout the simulated treatment. This indirectly indicates that
clinical outcome becomes more favorable as GC effectivity increases. Variation in GC





































































Clearance Slow Clearance Death
Figure 3.7. Depiction of changes in cellular dynamics as GC effectivity changes. In each
panel, the clinical outcome of clearance (i.e., patient survival) is in solid green, the clinical
outcome of slow clearance (prolonged survival) is in dashed blue curve, and the clinical
outcome of death is in dotted red. Variation in GC parameters did not produce clinical
outcome of tumor relapse.
3.4 Regulatory T Cell Experimental Simulation
Based on the immunosuppressive activity of regulatory T cells outlined in Section 1.6.3,
Treg effects can be modeled by their influence on corresponding model parameters. Param-
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eters that change with varying levels of Treg activity are:
• δD0 - naive dendritic cell death rate (changes due to Tregs killing DCs)
• εA - proliferation constant for CTLs (changes due to Treg interference)
• k - death scaling constant for active CTLs (changes due to Tregs killing CTLs)
• η - migration rate for dendritic cells to lymph nodes (changes due to Treg interference).
Using LHS of Treg parameters, we randomly sampled 1000 different parameter sets
from each Treg parameter’s uniform distribution. Sampled parameters were then scaled to
a conservative range about each predefined baseline parameter value. The model was solved
for each parameter set with fixed initial conditions to produce results shown in Figures 3.8
and 3.9, which are classified according to overall tumor burden dynamics outlined previously
in Section 3.2.
The motivation for using LHS of Treg parameters primarily comes from the desire to
efficiently explore the Treg parameter space. The interpretation of the hypercube matrix
output is that each row corresponds to a unique level of Treg effectivity. The uniqueness
comes from the fact that each row contains no identical entries to any other row. This
is highly representative of the random variability in each individual’s immune parameters.
However, since we desire to search a Treg parameter space with a much larger range than
would generally be attributed to natural individual variation, we may also interpret each
row of the hypercube matrix to represent the effects of various immunosuppressive drugs
on Treg activity.
We interpreted the hypercube generated with Treg parameters as a combination of
1000 different patients undergoing immunotherapy treatment with the aid of some kind
of immunosuppressive drug inhibiting Treg activity. As shown in Figure 3.8, the model
simulations have sufficient variability to be partitioned with each of our clinical treatment
outcome definitions. The first column of Figure 3.8 represents the change in tumor burden
dynamics as Treg effectivity increases from top to bottom (primary-solid blue and metastatic
dashed-red). In the second column, the most obvious variability exists in the lymphatic
dendritic cell population (solid-black). In the best case (clearance), lymphatic dendritic
cells saturate the lymph nodes for the majority of the simulated study period.
Ultimately, clinical treatment outcome appears to be most strongly correlated with
CTL dynamics shown in the third column. There is an obvious decline in active CTL load
































































































































Figure 3.8. For each clinical outcome (corresponding to figure rows) defined by tumor
dynamics, simulations for each cell type are shown. This figure demonstrates how clinical
outcome is highly correlated with the maintenance of CTLs throughout the simulated
treatment. This indirectly indicates that clinical outcome becomes more favorable as Tregs
become less effective in killing CTLs. Horizontal axes represent time in days.
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lower than proliferative stage CTL load (dashed-orange). This is an indication that Tregs
are either killing active CTLs most efficiently or interfering with proliferation in the last
row of Figure 3.8. Dynamics of all cells are driven by the complex combination of all Treg




































































Clearance Slow Clearance Relapse Death
Figure 3.9. Depiction of changes in cellular dynamics as Treg activity changes. In each
panel, the clinical outcome of clearance (i.e., patient survival) is in solid green, the clinical
outcome of slow clearance (prolonged survival) is in dashed blue curve, the clinical outcome
of relapse (possible prolonged survival) is in dotted purple, and the clinical outcome of death
is in dotted-dashed red.
Figure 3.9 shows each clinical outcome for selected cells on the same plot. Primary tumor
dynamics are given in Figure 3.9(A) with the clearance (solid green), slow clearance (dashed
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blue), relapse (dotted purple), and death (dashed and dotted red). Results are similar in
Figure 3.9(B), but represent metastatic tumor dynamics instead. As stated previously in
the discussion of Figure 3.8, the dendritic cell populations do not exhibit a large degree
of sensitivity to Treg parameters. This conclusion is supported by Figure 3.9(C), which
shows very little variation in lymphatic DC dynamics. The strongest correlation between
the tumor dynamics, as they are clinically defined, and immune dynamics comes from
Figure 3.9(D). Clearance, the ideal clinical outcome, is correlated with the highest CTL
load (solid green curve). As Treg effectivity increases, CTL load decreases and tumor
dynamics reflect less favorable clinical outcomes.
Based on Table 3.2, the outcomes shown in Figure 3.8 and Figure 3.9 are understandable.
Naive dendritic cell death increases from clearance to death, CTL fatalities increase from
clearance to death, and CTL proliferation decreases from clearance to death. Dendritic cell
migration does not follow an intuitive trend since the relapse and death cases occur with the
highest migration rates. However, this simply reflects the model’s negligible sensitivity to
changes in dendritic cell migration rates in comparison to changes in proliferation or death
rates for CTLs.
Table 3.2. Changes in Treg parameters from one clinical treatment outcome to the next.
δD0 is the naive DC death rate, k is the active CTL death constant, η is the migratory rate
for migrating DCs, and εA is the proliferation factor of CTLs.
Outcome δD0 k η εA
Clearance 0.006218062 1.817664 2.954493 4.052652
Slow
Clearance
0.006218062 4.490838 1.10697 3.138794
Relapse 0.02390397 9.126924 3.046669 3.047921




The interactions between dendritic cells, the complete T cell repertoire, and antibodies
with cancerous tumor cells and their antigens has been modeled as a system of first order
ordinary differential equations [67, 68]. However, the overall treatment/post-treatment
dynamics can be captured by explicitly modeling only laser treatment, DCs, the cytotoxic
T cell subset, primary and metastatic tumor cells, and tumor antigen (see Equations 2.1
and B.1).
Ultimately, in this thesis we neglected explicit treatment of helper T cells, B cells,
and antibodies while achieving similar tumor dynamics. We justify the omission of such
immune components based on the fact that CTL effectivity is partially a function of
the activity of helper T cells and B cells. This means that a reparameterization of our
reduced-equation model (Equations 2.1) accounts for the effects of helper T cells and B
cells. This allows for a significant reduction in the number of unknown model parameters
and allows us to experiment with the effects of implicitly modeled components through
strategic reparameterization.
Analysis presented in Chapter 3 suggests that anti-tumor laser immunotherapy can be
accurately simulated with models like those presented in Chapter 2. As shown in Figure 3.3,
the model is capable of simulating post-treatment tumor dynamics similar to those seen
experimentally [15]. Because the model parameters are biologically realistic, the model can
be used for clinical treatment outcome predictions.
Systematically studying the effects of glycated chitosan and regulatory T cells with
LHS leads to diverse changes in tumor burden dynamics. The clinical outcome definitions
outlined in Chapter 3 allowed for partitioning of model simulations as a function of GC and
Treg parameters. It is important to make clinical outcome definitions to determine how
successful treatment will be for any given set of parameters or initial conditions.
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Treg analysis suggests that a drug used for Treg suppression needs to primarily inhibit
their ability to affect CTL death and proliferation, because clinical outcomes correlate most
strongly with changes in CTL load over the course of the simulated study period (Figure 3.8).
Treg effects on dendritic cells in model simulations suggest a more complex relationship
between clinical outcome and DC dynamics; there is not a large degree of variability in DC
dynamics between the outcome cases. GC analysis suggests that clinical outcomes may be
less sensitive to changes in GC parameters than in the case for Treg parameters. However,
tumor dynamics still exhibit enough variability to partition simulations with three of the
defined clinical outcomes (Figure 3.6).
4.2 Suggested experiments
The analysis of anti-tumor laser immunotherapy from a modeling perspective suggests
a variety of experimental treatments to be performed in the laboratory. The following list
discusses a few experiments that might be useful in improving treatment efficacy.
1. Since it is possible to extract CTLs for the purpose of priming for a particular invader,
one suggestion would be to pursue this possibility alongside laser treatment. The goal
would be to train CTLs to attack the treated tumor cell line and build a substantial
CTL load for injection into the patient. The motivation comes from the fact that early
tumor infiltration is best in order to eradicate tumors. An injected population could
theoretically begin attacking primary and metastatic tumors soon after treatment before
a second line of activated CTLs arrives. This theory is supported by results found in
Section 3.2 (Figure 3.5).
2. Train dendritic cells before re-injecting them. The ultimate goal would be to activate as
many CTLs as possible, which might be enhanced through a larger number of primed
dendritic cells (Figure 3.5).
3. The timing of treatment tends to be crucial to patients with aggressively growing tumors.
Typically, treatments in anti-tumor laser immunotherapy are performed 7 to 10 days
post-inoculation. A possible experiment might be to wait a longer period of time before
treatment so that treatment efficacy could be tested in a much later stage of tumor
development.
4. Since tumor dynamics seem to be most closely tied to changes in Treg parameters, it
might be beneficial to try to derive a drug that either decreases the number of Tregs or
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mitigates their ability to kill CTLs or affect CTL proliferation. The latter drug effect is




Many tumors exhibit growth patterns that cannot be explained with a simple exponen-
tial growth model. Exponential growth is used in the current model of anti-tumor laser
immunotherapy because the tumor burden data suggests this type of growth. However,
we can use the model to look at this treatment for other tumor cell lines. Some tumors




. The logistic growth model includes
the assumption that there is some carrying capacity K that will affect overall population
dynamics. This carrying capacity is a type of ceiling for tumor growth, which is related to
nutrient availability and space. It would be quite simple to substitute a logistic term into
the primary and metastatic tumor equations to study other tumor types. The current model
can be used to study laser immunotherapy on any tumor cell line that exhibits exponential
growth. This would simply call for a reparameterization of the current model to account
for differences between tumor types.
The laser-tissue interaction in anti-tumor immunotherapy is much more complex than
the simple time-dependent treatment function used in the current model. In order to truly
understand primary tumor cell death as a function of laser heat, it is necessary to determine
how heat diffuses through a non-homogeneous tumor mass to produce cell death. This calls
for an application of the heat equation. The ability to quantify tumor cell death as a function
of heat shock would allow us to update the treatment function in the current model.
5.2 Experimentation
The model can easily be used to test experiments that are expensive to perform in the
laboratory setting. One such experiment would be to simulate the injection of a pre-primed
population of CTLs post-treatment to study how this would affect tumor dynamics. This
could be done by first solving the model until simulated injection was to take place and
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then using the output as the initial conditions for post-injection dynamics. The CTL initial
condition would dramatically increase for the post-injection period. This could also be
done for dendritic cells by changing the initial condition for DCs after simulated injection
of pre-primed DCs.
As described in the previous section, the model could be reparameterized to study other
exponentially growing tumor lines undergoing laser immunotherapy. For tumors that reach
a carrying capacity well before the death of the patient, the logistic growth model might
be more accurate. With a minor change to the primary and metastatic tumor equations,
simulated laser immunotherapy treatment could be performed on tumors expected to exhibit
logistic growth.
5.3 Speculation
Based on the model’s sensitivity to changes in CTL dynamics, simulating the injection
of pre-primed CTLs would most likely yield a more successful treatment. Theoretically, this
should also be true if performed in the laboratory alongside anti-tumor laser immunotherapy.
Since the model is less sensitive to DC dynamics, one could surmise that clinical out-
comes would not be as sensitive to changes in DC populations by priming DCs outside
the patient. If GC primarily affects dendritic cells, this would indicate that changes in
GC administration should not have extreme implications for clinical treatment outcomes.
However, considering the comparison of clinical outcomes influenced by GC versus other
common adjuvants shown in [16], the effects of GC may be more complex than our current
understanding yields.
It may be most important to focus on methods to suppress Tregs due to the model’s
enhanced sensitivity to Treg parameters. If it is possible to suppress these cells in the tumor
microenvironment for an extended period of time, then the model suggests that CTLs will




In our initial model, tumors were destroyed almost instantly with the chosen parameter-
ization. Based on the tumor burden data, this time course was not accurate. The proposed
mechanism behind the model on the next page is that antibody production is essential
to tumor cell destruction. This possible mechanism was suggested in [11], so we chose to
extend the model based on this hypothesis.
Since B cells produce antibodies upon activation, this required modeling three stages of
B cell development. However, activation of B cells requires stimulus by activated helper T
cells after B cells have received antigen via dendritic cells. Therefore, we modeled helper
T cells, B cells, and antibodies in order to account for a delay in tumor cell destruction.
Once tumors are tagged by selective antibodies, activated CTLs can then recognize them
for destruction. We also hypothesized that tumors may shed antibodies after some time, so
this introduced a small amount of feedback into the model. That is, tagged tumors could be
recycled back into the untagged tumor population and escape immune surveillance. This
meant that only sufficient antibody concentration would ultimately lead to a successful
treatment.
Upon further investigation of the antibody-induced tumor cell killing mechanism, we
could not reasonably conclude that this was the model that best fit the biology. This
divergence was based on several immunological facts that were previously unknown. One
of which, is fact that activated CTLs only need to be primed by a specific antigen in order
to effectively eradicate an invader. Evidence of this is given by studies in which CTLs
are extracted and trained to attack a specific tumor cell line and then re-injected, which
eventually leads to complete tumor destruction.
With new parameterization of the original model, we were able to accurately simulate
what is shown in tumor burden data. This allowed us to re-adopt a smaller model that is
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computationally more manageable and biologically more accurate. As before, the function

















































































= ρφ(t)P0 + pTA(λ0P0 + λ0M0 + λ1M1 + λ1P1)− (ω + αAc)D0
(A.1)
Excluding the antibody-mediated tumor cell destruction mechanism for post-treatment
dynamics, we can remove all B cell, helper T cell, and antibody related equations to
produce our initial model without CTL proliferation. This reduces the number of tumor
cell equations that we must track for post-treatment dynamics. Essentially, four tumor cell
equations in the expanded model become two equations in the reduced model.
APPENDIX B
REDUCED MODEL WITHOUT CTL
PROLIFERATION
With the reduced model without CTL proliferation, we have been able to accurately
predict clinical treatment outcomes as a function of GC and Treg effectivity. This model
has been very useful in that it has the capacity to explain a very complex system of events
taking place in anti-tumor immunotherapy, but it is also relatively small and easy to explain.
Interactions, in particular CTL-tumor cell interaction, are all modeled with mass-action
kinetics. However, CTL dynamics are not perfectly portrayed since overall numbers of
these cells are considerably low upon activation and tumor cell killing is simply too efficient.
Also, this model is quite stiff so solving can produce a large degree of numerical error. The
































= ρφ(t)P + pTA(λPP + λMM)− ωAc − αAcD0
(B.1)
APPENDIX C
MODEL OF CTL PROLIFERATION
In order to model the delay in tumor cell destruction without arbitrarily changing
parameters to achieve this goal, we wrote the following proliferation model for CTLs upon
activation. The purpose of this was to simulate a more realistic number of CTLs after
activation and to accurately capture the time course of tumor - CTL interaction. Each
successive proliferative stage equation multiplies the addition from the previous proliferative
stage equation by some scaling factor εi in order to model cellular cloning from one stage
to the next. The end result is a large number of active CTLs that travels to the sites of
tumors and begins attacking them.




































= εAξT8 − kδT0TA
(C.1)
A comparison between CTL dynamics with and without proliferation is given in Fig-
ure C.1. Without proliferation, CTL killing of tumor cells must be extremely efficient
since the total number of CTLs at any given time is quite low. With the appropriate
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parameterization and mass-action killing, we have modeled post-treatment tumor dynamics
accurately with our non-proliferation model. However, this model is not the most accurate
fit for the underlying immunology and can produce extensive numerical error when solving
the model. Figure C.1 is plotted on a log-scale, so the difference between CTLs with

















Figure C.1. Comparison of CTL dynamics with proliferation (solid-red) and without
proliferation (dashed-purple). Plot is on a log scale, so overall CTL loads differ by several
orders of magnitude as shown by vertical axis labels.
APPENDIX D
NON MASS-ACTION VS. MASS-ACTION
TUMOR CELL KILLING
Tumor dynamics change significantly from those in model Equations B.1 by adding
proliferation into the model. Since there are so many CTLs after proliferation, killing




, we diverge from the concept of individual CTLs killing tumor cells. The latter
term allows us to track tumor dynamics as a function of CTL effectivity in killing. As
shown in the left panel of Figure D.1, primary tumor burden with proliferative CTLs
reaches a peak later in the simulated period and decays more slowly. Similarly in the
right panel of Figure D.1, metastatic tumor burden begins decaying much more slowly in
the proliferative case for CTLs. This is a direct result of the non mass-action killing found







































Figure D.1. Comparison of tumor dynamics with proliferation and non mass-action killing
(solid-red) and without proliferation and mass-action killing (dashed-purple). Left: Primary
tumor burdens. Right: Metastatic tumor burdens. Time scale is in days.
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